Insmed (NASDAQ:INSM) vs. Entera Bio (NASDAQ:ENTX) Critical Analysis

Entera Bio (NASDAQ:ENTX – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Entera Bio and Insmed, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio 1 0 4 1 2.83
Insmed 1 1 23 1 2.92

Entera Bio presently has a consensus target price of $9.60, suggesting a potential upside of 217.67%. Insmed has a consensus target price of $196.52, suggesting a potential upside of 61.94%. Given Entera Bio’s higher probable upside, research analysts clearly believe Entera Bio is more favorable than Insmed.

Risk & Volatility

Entera Bio has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

14.1% of Entera Bio shares are held by institutional investors. 3.7% of Entera Bio shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Entera Bio and Insmed”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio $40,000.00 13,156.28 -$11.44 million ($0.39) -7.75
Insmed $606.42 million 43.90 -$1.28 billion ($2.82) -43.03

Entera Bio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Entera Bio and Insmed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entera Bio N/A -38.55% -36.15%
Insmed -39.85% -96.38% -32.55%

Summary

Entera Bio beats Insmed on 10 of the 14 factors compared between the two stocks.

About Entera Bio

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.